CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03311334
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:49.289761+00:00
Published At: 2024-04-18T00:00:00+00:00
Record Updated At: 2024-04-18
Results Posted At: 2024-04-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Renal Cell Carcinoma (RCC)", "Urothelial Carcinoma", "Primary Peritoneal Cancer", "Platinum-resistant Ovarian Cancer (PROC)", "Serous Epithelial Ovarian Cancer", "Fallopian Tube Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2024-04-18"
protocolSection.identificationModule.nctId: "NCT03311334"
protocolSection.identificationModule.officialTitle: "A Phase 1b/2, Multicenter, Open-Label Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Pembrolizumab in Adult Patients With Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2024-04-18"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.